Triethylamine → 6-morpholin-4-yl-pyridine-3-sulfonic acid 9-benzhydryloxy-7-(4-fluoro-benzyl)-8-oxo-7,8-dihydro-6H-pyrrolo[3,4-g]quinolin-5-yl ester

HRID 853672Notizen

Reaktionsgleichung

Reaktionsgleichung von HRID 853672
C(N(CC)CC)C.[N:8]1([C:14]2[N:19]=[CH:18][C:17]([S:20](Cl)(=[O:22])=[O:21])=[CH:16][CH:15]=2)[CH2:13][CH2:12][O:11][CH2:10][CH2:9]1.[CH:24]([O:37][C:38]1[C:39]2[C:51](=[O:52])[N:50]([CH2:53][C:54]3[CH:59]=[CH:58][C:57]([F:60])=[CH:56][CH:55]=3)[CH2:49][C:40]=2[C:41]([OH:48])=[C:42]2[C:47]=1[N:46]=[CH:45][CH:44]=[CH:43]2)([C:31]1[CH:36]=[CH:35][CH:34]=[CH:33][CH:32]=1)[C:25]1[CH:30]=[CH:29][CH:28]=[CH:27][CH:26]=1.CCOC(C)=O.CCCCCC>CN(C1C=CN=CC=1)C.CCOC(C)=O>[CH:24]([O:37][C:38]1[C:39]2[C:51](=[O:52])[N:50]([CH2:53][C:54]3[CH:59]=[CH:58][C:57]([F:60])=[CH:56][CH:55]=3)[CH2:49][C:40]=2[C:41]([O:48][S:20]([C:17]2[CH:18]=[N:19][C:14]([N:8]3[CH2:9][CH2:10][O:11][CH2:12][CH2:13]3)=[CH:15][CH:16]=2)(=[O:22])=[O:21])=[C:42]2[C:47]=1[N:46]=[CH:45][CH:44]=[CH:43]2)([C:25]1[CH:30]=[CH:29][CH:28]=[CH:27][CH:26]=1)[C:31]1[CH:32]=[CH:33][CH:34]=[CH:35][CH:36]=1

Komponenten

7

Versuchsvorschrift

Triethylamine (50 μl), DMAP (catalytic amount) and 6-Morpholin-4-yl-pyridine-3-sulfonyl chloride (26.3 mg, 0.10 mmol) were added to 0.034 mmol 45. The reaction mixture was stirred at room temperature for 18 hours under an inert atmosphere. The reaction was monitored by TLC (EtOAc/hexane 3/7) (Rf 44=0.5, Rf 45=0, Rf 266=0.3) and LC/MS. After completion of the reaction, the mixture was diluted with EtOAc (20 mL) and washed with 1N HCl, saturated NaHCO3 and brine. The organic phase was dried (MgSO4), filtered and concentrated in vacuo. The residue was purified by silica gel chromatography (ethylacetate/hexane—3/7) to afford 6-morpholin-4-yl-pyridine-3-sulfonic acid 9-benzhydryloxy-7-(4-fluoro-benzyl)-8-oxo-7,8-dihydro-6H-pyrrolo[3,4-g]quinolin-5-yl ester 266 (14.6 mg, 59%).

Aufarbeitung

  1. customAfter completion of the reaction
  2. washwashed with 1N HCl, saturated NaHCO3 and brine
  3. dry with materialThe organic phase was dried (MgSO4)
  4. filtrationfiltered
  5. concentrationconcentrated in vacuo
  6. customThe residue was purified by silica gel chromatography (ethylacetate/hexane—3/7)

Quellen und Nachweise

ORD-Eintrag
ord-1d684a5d284245c09a08a2dec3171b66
Quelldatensatz
uspto-grants-2007_08
Patentnummer
US07253180B2

Notizen zur Reaktion

Wird geladen…